AU2015266614A1 - Use of secoisolariciresinol diglucosides (SDGs) and related compounds for protection against radiation and chemical damage - Google Patents

Use of secoisolariciresinol diglucosides (SDGs) and related compounds for protection against radiation and chemical damage Download PDF

Info

Publication number
AU2015266614A1
AU2015266614A1 AU2015266614A AU2015266614A AU2015266614A1 AU 2015266614 A1 AU2015266614 A1 AU 2015266614A1 AU 2015266614 A AU2015266614 A AU 2015266614A AU 2015266614 A AU2015266614 A AU 2015266614A AU 2015266614 A1 AU2015266614 A1 AU 2015266614A1
Authority
AU
Australia
Prior art keywords
sdg
subject
radiation
exposed
bioactive ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015266614A
Other languages
English (en)
Inventor
Melpo Christofidou-Solomidou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of AU2015266614A1 publication Critical patent/AU2015266614A1/en
Priority to AU2020270469A priority Critical patent/AU2020270469A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
AU2015266614A 2014-05-30 2015-06-01 Use of secoisolariciresinol diglucosides (SDGs) and related compounds for protection against radiation and chemical damage Abandoned AU2015266614A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020270469A AU2020270469A1 (en) 2014-05-30 2020-11-16 Use of secoisolariciresinol diglucosides (SDGs) and related compounds for protection against radiation and chemical damage

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462005330P 2014-05-30 2014-05-30
US62/005,330 2014-05-30
US201562101296P 2015-01-08 2015-01-08
US62/101,296 2015-01-08
PCT/US2015/033501 WO2015184441A2 (en) 2014-05-30 2015-06-01 USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION AND CHEMICAL DAMAGE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020270469A Division AU2020270469A1 (en) 2014-05-30 2020-11-16 Use of secoisolariciresinol diglucosides (SDGs) and related compounds for protection against radiation and chemical damage

Publications (1)

Publication Number Publication Date
AU2015266614A1 true AU2015266614A1 (en) 2016-12-15

Family

ID=54700083

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015266614A Abandoned AU2015266614A1 (en) 2014-05-30 2015-06-01 Use of secoisolariciresinol diglucosides (SDGs) and related compounds for protection against radiation and chemical damage
AU2020270469A Abandoned AU2020270469A1 (en) 2014-05-30 2020-11-16 Use of secoisolariciresinol diglucosides (SDGs) and related compounds for protection against radiation and chemical damage

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020270469A Abandoned AU2020270469A1 (en) 2014-05-30 2020-11-16 Use of secoisolariciresinol diglucosides (SDGs) and related compounds for protection against radiation and chemical damage

Country Status (9)

Country Link
EP (1) EP3148560A4 (enExample)
JP (2) JP2017520620A (enExample)
KR (1) KR20170010019A (enExample)
CN (2) CN107155304A (enExample)
AU (2) AU2015266614A1 (enExample)
CA (1) CA2950744A1 (enExample)
IL (1) IL249219A0 (enExample)
MA (1) MA39899A (enExample)
WO (1) WO2015184441A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017214039A1 (en) * 2016-06-07 2017-12-14 University Of Pennsylvania Compositions and methods for protecting organs from ischemia/reperfusion injury associated with transplantation
WO2018187272A1 (en) * 2017-04-03 2018-10-11 Gusto Global, Llc Rational design of microbial-based biotherapeutics
US20210128596A1 (en) * 2017-09-27 2021-05-06 University Of Pennsylvania Compositions and methods for treating septic cardiomyopathy
WO2019067729A1 (en) * 2017-09-27 2019-04-04 The Trustees Of The University Of Pennsylvania USE OF SECO-SOLARICINESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS IN THE PROTECTION AGAINST RADIATION-INDUCED CARDIOVASCULAR DYSFUNCTIONS
EP3843557B1 (en) * 2018-08-31 2023-09-20 Innophos, LLC An extract of anacardium occidentale for use in treating oxidation induced dna damage
CN116850162A (zh) * 2023-08-08 2023-10-10 南通大学附属医院 肠二醇在制备治疗放射性肠炎药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486126B1 (en) * 1999-06-30 2002-11-26 University Of Saskatchewan Technologies Incorporated Antioxidant activity in SDG metabolites
WO2001095901A1 (en) * 2000-06-14 2001-12-20 Alla Shapiro Radioprotective agents
CN100365005C (zh) * 2006-03-02 2008-01-30 江南大学 一种从亚麻籽中提取纯化开环异落叶松树脂酚二葡萄糖苷的方法
US20070293458A1 (en) * 2006-06-16 2007-12-20 Ip-6 Research Inc. Prevention of nuclear, solar, and other radiation-induced tissue damage
WO2008147563A1 (en) * 2007-05-25 2008-12-04 The Trustees Of The University Of Pennsylvania Flaxseed lignan complex, methods of using and compositions thereof
EP2340034B2 (en) * 2008-08-07 2019-02-13 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Radioprotectants targeting thrombospondin-1 and cd47
CN101759731B (zh) * 2008-12-25 2011-10-19 中国科学院兰州化学物理研究所 亚麻籽胶和开环异落叶松树脂酚二葡萄糖苷的提取方法
ES2691845T3 (es) * 2013-06-10 2018-11-28 The Trustees Of The University Of Pennsylvania Preparación de (S,S)-secoisolariciresinol diglucósido y (R,R)-secoisolariciresinol diglucósido

Also Published As

Publication number Publication date
EP3148560A4 (en) 2018-04-25
IL249219A0 (en) 2017-02-28
WO2015184441A9 (en) 2016-01-21
MA39899A (fr) 2021-05-26
CN112336736A (zh) 2021-02-09
JP2017520620A (ja) 2017-07-27
CA2950744A1 (en) 2015-12-03
EP3148560A2 (en) 2017-04-05
KR20170010019A (ko) 2017-01-25
JP2020121987A (ja) 2020-08-13
WO2015184441A3 (en) 2016-03-10
AU2020270469A1 (en) 2020-12-17
CN107155304A (zh) 2017-09-12
WO2015184441A2 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
AU2020270469A1 (en) Use of secoisolariciresinol diglucosides (SDGs) and related compounds for protection against radiation and chemical damage
Zhou et al. Rhein regulates redox‐mediated activation of NLRP3 inflammasomes in intestinal inflammation through macrophage‐activated crosstalk
Bareggi et al. Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders
Ghasemi-Pirbaluti et al. The effect of menthol on acute experimental colitis in rats
Wang et al. C-phycocyanin mitigates cognitive impairment in doxorubicin-induced chemobrain: impact on neuroinflammation, oxidative stress, and brain mitochondrial and synaptic alterations
Mei et al. FA-97, a new synthetic caffeic acid phenethyl ester derivative, ameliorates DSS-induced colitis against oxidative stress by activating Nrf2/HO-1 pathway
Wu et al. Protective effects of Flagellin a N/C against radiation-induced NLR Pyrin domain containing 3 Inflammasome-dependent Pyroptosis in intestinal cells
Moussa et al. A low dose of fermented soy germ alleviates gut barrier injury, hyperalgesia and faecal protease activity in a rat model of inflammatory bowel disease
US10966995B2 (en) Use of secoisolariciresinol diglucosides (SDGS) and related compounds for protection against radiation and chemical damage
Djordjevic et al. Fluoxetine affects antioxidant system and promotes apoptotic signaling in Wistar rat liver
RU2764175C1 (ru) Бифункциональные композиции для лечения рака
Tottori et al. Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523
Aldbass et al. Protective and therapeutic potency of N-acetyl-cysteine on propionic acid-induced biochemical autistic features in rats
JP2025119055A (ja) 癌治療
Ju et al. Corydalis saxicola bunting total alkaloids attenuate walker 256-induced bone pain and osteoclastogenesis by suppressing RANKL-induced NF-ΚB and c-FOS/NFATc1 pathways in rats
Galvani et al. Protective Activity of Melatonin Combinations and Melatonin‐Based Hybrid Molecules in Neurodegenerative Diseases
Li et al. 17-AAG post-treatment ameliorates memory impairment and hippocampal CA1 neuronal autophagic death induced by transient global cerebral ischemia
Zhao et al. Epimedium polysaccharides ameliorate ulcerative colitis by inhibiting oxidative stress and regulating autophagy
Deng et al. Discovery of a novel chalcone-derived covalent Keap1 binder for mitigating cisplatin-induced mitochondrial dysfunction and nephrotoxicity
Cuzzocrea et al. Synergistic interaction between methotrexate and a superoxide dismutase mimetic: pharmacologic and potential clinical significance
HK1240082A1 (en) Use of secoisolariciresinol diglucosides (sdgs) and related compounds for protection against radiation and chemical damage
JP2020512408A (ja) 肺がんの治療に使用するための組み合わせ
Srivastava et al. Chronic kidney disease amplifies severe kidney injury and mortality in a mouse model of skin arsenical exposure
WO2023192918A2 (en) Anti-oncogenic phytochemicals and methods and uses for treating cancer
Mukawa et al. Inhibitory effects of the cyclooxygenase-2 inhibitor, etodolac, on colitis-associated tumorigenesis in p53-deficient mice treated with dextran sulfate sodium

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted